Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
CRANBURY, N.J., May 09, 2017 -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics, today announced that Pankaj Mohan, Ph.D., Chairman and Chief Executive Officer of Oncobiologics, will participate and present at the World Biosimilar Congress 2017 taking place May 23 – 24, 2017.
Event: The World Biosimilar Congress 2017
Presentation Date: May 23-24, 2017
Location: Hilton San Diego Resort and Spa, San Diego, CA
Dr. Mohan will present on “Production efficiency: Streamlining both the development and manufacturing process,” on May 23rd at 3:20 p.m. On the same day, Dr. Mohan will also participate in a panel discussion on Intellectual Property at 5:00 p.m. On May 24th at noon, he will moderate a roundtable discussion of industry executives on “Achieving required data for regulatory and commercial approvals.”
World Biosimilar Congress 2017
To learn more about the World Biosimilar Congress and to register for the conference please visit http://www.terrapinn.com/conference/biosimilar-congress-usa/index.stm
About Oncobiologics, Inc. and its BioSymphony™ Platform
Oncobiologics is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Its current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. Oncobiologics is advancing its pipeline of eight biosimilar products, two of which are currently in clinical development. Led by a team of biopharmaceutical experts, Oncobiologics operates from an in-house state-of-the-art fully integrated research and development, and manufacturing facility in Cranbury, New Jersey. Oncobiologics employs its BioSymphony™ Platform to address the challenges of biosimilar development and commercialization by developing high quality mAb biosimilars in an efficient and cost-effective manner on an accelerated timeline. For more information, please visit www.oncobiologics.com
CONTACTS: Oncobiologics: Lawrence A. Kenyon Chief Financial Officer [email protected] Media & Investors: Alex Fudukidis Russo Partners, LLC [email protected]
